Specific treatments for (pediatric) acute myeloid leukemia (AML) are lacking.
Standard treatments still include intensive myelosuppressive chemotherapy, which is unsatisfactory in terms of general toxicity, with the persistent risk of relapse due to the escape of quiescent leukemic cells to chemotherapy. Importantly, only 11 to 23 % of pediatric patients diagnosed with the most aggressive leukemia subtype harboring a known genetic rearrangement are designated as event-free survivors at 5 years.
Our invention relates to novel analogs of thioridazine, that lack a characteristic CNS toxicity of the parent molecule, for a targeted treatment of the most aggressive pediatric subtype of acute myeloid leukemia (t(6;11)AML featuring disease free survival at 5 years of only 11-23%).


Lead Optimization/Preclinical





Download the brochure

  • Small molecule inhibitors of OPA1 GTPase activity with anti-cancer properties

    Cancer is a complex disease resulting from the interplay between the tumor cell and its microenvironment, featuring impaired apoptosis and activation of quiescent blood vessels to induce neovascularization to support metastasis. Two of the yet unmet needs in anticancer therapy[...]

  • A novel treatment for diabetic ulcers

    Diabetic chronic ulcers, a common complication of diabetes, are significant cause of morbidity and mortality in the Western world. Despite the considerable medical need, currently no specific and efficacious treatment for diabetic -and other chronic- ulcers exist. This is in[...]

  • Novel Regulated Promoter for Gene Therapy

    Neuroinflammation, characterized by microglial cell-activation, plays a major role in the pathogenesis and progression of multiple neurodegenerative diseases, such as Lysosomal Storage Disorders and Alzheimer’s, severe human conditions currently lacking an effective treatment. Ex vivo gene therapy based on genetically[...]

Subscribe to newsletter

Follow the activities promoted by UniSMART Foundation